MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

"Patients will receive 200 mg Pembrolizumab on Day -28 and Day -6 by IV infusion.~Pembrolizumab 200 mg IV will resume at day 30+ after ASCT every 3 weeks for 1 year."

On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.

Patient will receive a single dose of BCNU on day -6, dose of 300 mg/m2 by IV infusion.

Etoposide will be given at dose 100 mg/m2 BID intravenously on days -5, - 4, -3, and -2.

Cytarabine will be given at dose 100 mg/m2 BID intravenously on days -5, -4, - 3, and -2.

Melphalan will be given at dose of 140 mg/m2 intravenously on day -1 in a single 20 minute infusion; dose will be based on actual body weight but capped at 3.6 mg/kg as part of BEAM conditioning.